Publications by authors named "Alizee Ballarin"
J Immunother Cancer
July 2024
Article Synopsis
- - TLR9 agonists, particularly nelitolimod, enhance the immune response against liver tumors by promoting the killing of micro-organisms and cancer cells, although their effectiveness is limited by specific immune cell behaviors and drug delivery challenges.
- - A new delivery method called pressure-enabled drug delivery (PEDD) improves the targeting of TLR9 agonists to tumors, leading to increased depletion of suppressive immune cells (MDSCs) and overall immune stimulation, especially when combined with checkpoint inhibitors.
- - In experiments with mice, the system showed promising results when nelitolimod was given directly to the tumor alongside either systemic or subcutaneous administration of immune checkpoint inhibitors, resulting in notable changes in immune cell populations within the tumors.
